Adriamycin & cyclophosphamide (AC) followed by docetaxel (D) versus AC followed by paclitaxel (P) in operable node positive breast cancer

被引：0
|
作者：
Abdel-Halim, I. [1 ]
Ei-Sadda, W. [1 ]
机构：
[1] Mansoura Univ, Sch Med, Mansoura, Egypt
来源：
BREAST | 2011年 / 20卷
关键词：
D O I：
10.1016/S0960-9776(11)70216-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S65 / S65
页数：1
相关论文
共 50 条
  • [31] Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506)
    Inhwan Hwang
    Jeong Eun Kim
    Jae Ho Jeong
    Jin-Hee Ahn
    Kyung Hae Jung
    Byung Ho Son
    Hak Hee Kim
    Junyoung Shin
    Hee Jin Lee
    Gyungyub Gong
    Sung-Bae Kim
    [J]. Breast Cancer Research and Treatment, 2023, 201 : 193 - 204
  • [32] Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506)
    Hwang, Inhwan
    Kim, Jeong Eun
    Jeong, Jae Ho
    Ahn, Jin-Hee
    Jung, Kyung Hae
    Son, Byung Ho
    Kim, Hak Hee
    Shin, Junyoung
    Lee, Hee Jin
    Gong, Gyungyub
    Kim, Sung-Bae
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2023, 201 (02) : 193 - 204
  • [33] Efficacy results of node-negative HER2-amplified breast cancer subset from BCIRG 006 study: A phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin, and trastuzumab (TCH).
    Valero, V.
    Slamon, D. J.
    Eiermann, W.
    Robert, N. J.
    Pienkowski, T.
    Martin, M.
    Mackey, J. R.
    Lindsay, M. A.
    Bee-Munteanu, V.
    Press, M. F.
    Sauter, G.
    Crown, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [34] Primary systemic chemotherapy for operable breast cancer with docetaxel followed by cyclophosphamide, epirubicin, and fluorauracil (DOC-CEF)
    Kikawa, Y.
    Masai, Y.
    Hashimoto, T.
    Nakamoto, Y.
    Nishikawa, H.
    Takahara, S.
    Suwa, H.
    Tachibana, T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [35] Pathologic complete response (pCR) to preoperative sequential doxorubicin/cyclophosphamide (AC) and taxane (AC-T) or AC followed by paclitaxel and trastuzumab (AC-TH) in stage II-III HER2-positive breast cancer
    Chumsri, S.
    Jeter, S. C.
    Jacobs, L. K.
    Lange, J. R.
    Davidson, N. E.
    Emens, L. A.
    Fetting, J. H.
    Gabrielson, E.
    Zhang, Z.
    Stearns, V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] Cardiac safety analysis of the first stage of NSABP B-31, a randomized trial comparing the safety and efficacy of doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) to that of AC followed by paclitaxel plus trastuzumab (TH) in patients (pts) with operable, node-positive (N+), HER-2 overexpressing breast cancer (HER2+BC)
    Geyer, C.
    Bryant, J.
    Romond, E.
    Tan-Chiu, E.
    Ewer, M.
    Keefe, D.
    Shannon, R.
    Yothers, G.
    Wolmark, N.
    [J]. EJC SUPPLEMENTS, 2004, 2 (03): : 141 - 141
  • [37] Cardiac safety analysis of the first stage of NSABP B-31, a randomized trial comparing the safety and efficacy of Adriamycin® and cyclophosphamide (AC) followed by Taxol® to that of AC followed by Taxol® plus Herceptin® in patients (Pts) with operable, node-positive (N+), HER-2 overexpressing breast cancer (HER2+BC)
    Geyer, CE
    Bryant, J
    Romond, E
    Tan-Chiu, E
    Ewer, M
    Keefe, D
    Shannon, R
    Yothers, G
    Brown, A
    Fehrenbacher, L
    Vogel, V
    Seay, TE
    Flynn, PJ
    Wolmark, N
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S13 - S13
  • [38] Preoperative doxorubicin/cyclophosphamide followed by docetaxel (AC-Doc) versus dose-dense doxorubicin and docetaxel (Adoc) as preoperative treatment in operable breast cancer: first analysis of the event-free survival of the GeparDuo-Study.
    Raab, G
    Kaufmann, M
    Schuette, M
    Hilfrich, J
    Blohmer, JU
    Gerber, B
    Costa, SD
    Eidtmann, H
    Eiermann, W
    Lampe, D
    Jackisch, C
    du Bois, A
    von Minckwitz, G
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S222 - S222
  • [39] A phase II study to evaluate the feasibility of bi-weekly docetaxel followed by bi-weekly doxorubicin and cyclophosphamide as adjuvant therapy for operable breast cancer (T-AC).
    Lambert-Falls, R
    Ackerman, M
    Jones, GT
    Smith, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 88S - 88S
  • [40] A randomized phase Ill trial of neoadjuvant sequential chemotherapy with 4 cycles of adriamycin plus cyclophosphamide followed by 4 cycles of docetaxel (AC4-D4) versus shorter 3 cycles of FEC followed by 3 cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-Shorter): First report of efficacy & toxicity profile
    Kim, J. E.
    Ahn, J-H
    Jung, K. H.
    Lee, H. J.
    Gong, G-Y
    Lee, E-M
    Ha, E. J.
    Son, B-H
    Ahn, S-H
    Ahn, S. D.
    Kim, H-H
    Shin, H. J.
    Kim, S-B
    [J]. CANCER RESEARCH, 2016, 76
12345